Read Time: 2 mins

83/Baseline NYHA class predicts response to cardiac resynchronisation therapy at 6-months

Copy Link
Published Online: Sep 27th 2010 European Journal of Arrhythmia & Electrophysiology. 2020;6(Suppl. 1):abstr83
Authors: H Wilburn (Presenting Author) - Rotherham General Hospital, Rotherham; L Broadhurst - Rotherham General Hospital, Rotherham; S Smith - Rotherham General Hospital, Rotherham
Quick Links:
Article Information

Introduction: Cardiac resynchronisation therapy (CRT) is used in select heart failure patients1,2 to improve quality of life and mortality.3-5 Some patients are reported to experience no benefit; so called ‘non-responders’. This retrospective service evaluation aimed to determine the CRT response rate at Rotherham General Hospital (RGH), exploring which variables may be influencing response.

Methods: Medical records of CRT patients at RGH were reviewed. The following departmental definition of response was used: alive at 6-month follow-up with 2/3 of the following: ≥1 improvement in New York Heart Association (NYHA) class; ≥10% improvement in 6 Minute Walk Test; ≥15-point improvement in Minnesota Living with Heart Failure Questionnaire. Response was assessed for association with pre-defined variables.

Results: Of 69 patients included, response was 64%. Univariate logistic regression indicates that baseline NYHA class is the only significant predictor of response (χ2(1df, n=69) =7.288, p=0.007, OR=0.245, 95%CI [0.085, 0.709]). Patients with baseline NYHA III class were more likely to respond than NYHA II. Although no other variables showed statistically significant association with response, there was a trend towards higher response in females and with lateral LV lead position. There was also a trend towards a greater reduction in QRS duration in responders.

Discussion: CRT response at RGH is comparable to response rates reported in literature which used similar definitions of response.6,7 More severe heart failure at baseline was a significant predictor of response. Evidence of the benefits of CRT in NYHA III/IV patients in terms of functional improvements and symptom relief at 6-months is consistent.3,4 Based on data from larger trials, reported benefits of CRT in NYHA I/II patients appear to be more related to reduced hospitalisation and death over longer timeframes.5,8 Consideration is being made to adjust the departmental definition of response to incorporate a 3rd group of ‘non-progressors’. This may be a more accurate representation of CRT benefits in patients that have disease status halted or slowed, but not reversed.

Of those variables which did display a trend towards a positive association with response, the lack of statistical significance may be attributable to the relatively small sample size of this project. This was namely female sex, lateral LV lead position and greater reduction in QRS duration. These three variables have previously been reported by others to be associated with a positive response to CRT.6,9,10


  1. Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013;34:2281–2329.
  2. National Institute for Health and Care Excellence (NICE). 2014. Technology appraisal guidance TA314. Available at: (accessed September 2020).
  3. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA. 2003;289:2685–94.
  4. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344:873–80.
  5. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–38.
  6. Lecoq G, Leclercq C, Leray E, et al. Clinical and electrocardiographic predictors of a positive response to cardiac resynchronization therapy in advanced heart failure. Eur Heart J. 2005;26:1094–100.
  7. Notabartolo D, Merlino JD, Smith AL, et al. Usefulness of the peak velocity difference by tissue Doppler imaging technique as an effective predictor of response to cardiac resynchronization therapy. Am J Cardiol. 2004;94:817–20.
  8. Abraham WT, Young JB, León AR, et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation. 2004;110:2864–8.
  9. Cheng YJ, Zhang J, Li WJ, et al. More favorable response to cardiac resynchronization therapy in women than in men. Circ Arrhythm Electrophysiol. 2014;7:807–15.
  10. Loutfi M, Nawar M, Eltahan S, Elhoda AA. Predictors of response to cardiac resynchronization therapy in chronic heart failure patients. Egypt Heart J. 2016;68:227–36.

Further Resources

Share this Article
Related Content In Arrhythmia
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72